Table 2.

Clinical and pathological status, according to screening program.

	IBCG N = 155 (%)	PBCG N = 470 (%)	P value
Diagnosis by clinical examination of the breast	149	426	<0.00001
Yes	45 (30.0)	325 (76.0)
No	104 (70.0)	101 (24.0)
Clinical tumor size (TNM stage)	149	422	<0.00001
0 (tumor not palpable)	96 (64.0)	79 (19.0)
1 (<20 mm)	39 (26.0)	142 (33.0)
2 (20-50 mm)	14 (10.0)	141 (33.0)
3 (>50 mm)	0 (0)	47 (12.0)
4 (extension to skin/chest wall or inflammatory)	0 (0)	13 (0)
Clinical node involvement (TNM stage)	149	421	<0.00001
0	134 (90.0)	275 (75.0)
1 (1 to 3 lymph nodes involved)	13 (9.0)	134 (32.0)
2–3 (>4 lymph nodes involved)	2 (1.0)	12 (2.0)
Clinical M (TNM stage)	149	422	0.12
M0	149 (100.0)	412 (98.0)
M1	0 (0)	10 (2.0)
Histological type	152	463	<0.0001
DCIS	36 (23.7)	35 (7.6)
Low grade	4 (11.1)	3 (9)	NS
Intermediate grade	8 (22.2)	13 (37)
High grade	24 (66.7)	19 (54)
IDC	108 (71.0)	405 (87.5)
ILC+/−IDC	5 (3.3)	17 (3.6)
Other	3 (2.0)	6 (1.3)
Unknown	3	7
Molecular phenotype (invasive tumors)	115	422	NS
HER2+++	2 (1.7)	14 (3.3)
HR−/HER2−	61 (53.0)	201 (47.6)
HR−/HER2?	1 (0.9)	13 (3.0)
HR+/HER2?	1 (0.9)	27 (6.4)
HR+/HER2−	50 (43.6)	167 (39.7)
Unknown	4	13
Nodal status (invasive tumors)	119	435	<0.0001
Negative	84 (81.5)	185 (63.1)
Positive	19 (18.5)	108 (36.9)
Unknown	16	142
EE Grade	116	428	NS
I–II	41 (36.9)	139 (33.2)
III	70 (63.1)	280 (66.8)
Unknown	5	9

Abbreviations: IBCG: incident breast cancer group, PBCG: prevalent breast cancer group.

DCIS: ductal carcinoma in situ, IDC: invasive ductal carcinoma, ILC: invasive lobular carcinoma.

HER2+++: human epidermal growth factor receptor-2 amplified, HR: hormone receptor status.

Positive or negative. EE grade: Elston and Ellis grade.